argenx N.V.

US/Swiss biotech GlycoEra AG announced a $130m series B financing on 27 May that it says will enable it to advance its first protein-degradation drug candidate through Phase II proof of concept as pre

Roivant has promised investors it will spend some of its impressive cash stockpile on buying new assets. But midway into the year, no deals have been signed. CEO Matt Gline, in an interview at the com

Leo Pharma has posted a strong set of financials for the first quarter of 2025, “building on build on the momentum that we delivered in 2024,” CEO Christophe Bourdon has told Scrip . Revenues rose by

Johnson & Johnson’s Imaavy (nipocalimab) was approved by the US Food and Drug Administration for generalized myasthenia gravis (gMG), but the approval is the first of many the company hopes to sec